Investee Company Update: YRRO Ltd

RNS Number : 9932H
Craven House Capital PLC
09 December 2020
 

Certain information contained within this Announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 ("MAR"). Upon publication of this Announcement, this information is now considered to be in the public domain.

 

Craven House Capital plc

Investee Company Update: YRRO Ltd

Craven House Capital plc ("Craven" or the "Company"), the AIM quoted investment company, is pleased to reproduce the following announcement issued today by Black Sea Property AS ("BSP"), with regards to it entering into an option agreement to acquire certain business assets from YRRO Ltd ("Yrro"), an investee company specialising in the distribution and sale of dietary supplements, in which Craven has a 29.99% stake in.

For the six month period to 31 January 2020, YRRO, which was incorporated in July 2019, showed a loss of £25,883 and a net asset value at 31 January 2020 of £53,678.

"Black Sea Property as: Enters into option agreement to acquire Omega 3 and Collagen business

Black Sea Property AS ("BSP" or the "Company") hereby announces that it has entered into an option agreement (the "Option" and the "Option Agreement") to acquire certain business assets from YRRO Ltd ("Yrro"), a company incorporated in the UK and managed in Sweden, specialising in the distribution and sale of dietary supplements.

 

The Option provides BSP with the right, but not an obligation, to acquire at any time during the next six months the following brand names and all associated rights, including the benefit of sales, from Yrro:

 

· Omega 3, North Norway

-  Omega 3 NORTH NORWAY is a 100 % Omega 3 salmon oil.

-  Omega 3 NORTH NORWAY has a theme inspired by the North of Norway.

-  Further information is available at www.biovitos.com

 

· Royal Norwegian Fish Oil™

-  Royal Norwegian Fish Oil is a lifestyle brand of seven different Omega 3 products, with added vitamins and minerals, targeting specific lifestyle groups.

 

· Functional Omega 3

-  Functional Omega 3 is a brand of 12 different Omega 3 products, also with added vitamins and minerals, focusing on different physical and mental functions.

 

· Nor Can Oil

Yrro owns Nor Can Oil.com, a business importing and in the process of establishing sales prescription medical cannabis in Denmark. This company is applying for a licence from the Danish Medicines Agency to import, distribute and sell Omega 3 added with medical cannabis to Danish patients.

Nor Can Oil will also sell Omega 3 with added CBD oil.

-  Further information is available at: www.norcanoil.com

 

· Ocean Skin Lab

-  Ocean Skin Lab is a brand of different Marine Collagen products adding vitamins, minerals

-  Ocean Skin Lab will sell by subscription, as well as directly via B2B and as "private label" products

-  Further information is available at www.oceanskinlab.com

 

AMAZON sales:

Yrro is a registered professional seller on all Amazon platforms and will use these platforms to accelerate its Omega 3 distribution worldwide. Yrro will list seven different Omega 3 brands on Amazon in Germany, the UK, Sweden and, subsequently, in the US.

 

Egil Melkevik, chairman of the Company, comments: "In a time with significant uncertainty in the global tourism markets, this Option provides the Company and its shareholders with a potential for additional value creation and diversification of its investment in Black Sea Property. We look forward to following the development of Yrro in the coming six months, while continuing our work with the development of the Sunrise Gardens Hotel".

 

Cato Crogh, CEO of Yrro, comments: "As CEO and founder of Yrro, I see the potential transaction with Black Sea Property as strategically important for Yrro, and I am confident that it can offer the potential for a great boost in organic growth for our Omega 3 and health business. Going forward, we shall also look into opportunities for growth through acquisition, both in established and new markets for our product segment."

 

Under the terms of the Option Agreement, the purchase price for the assets will be NOK 130,000,000. The consideration payable upon exercise of the Option is to be settled by the issuance of new consideration shares in BSP to the shareholders of Yrro, whereby the shareholders of Yrro will receive an amount of shares in the Company corresponding to 85% of the outstanding shares in the Company following the Option exercise. The existing shareholders of BSP will consequently hold 15% of the shares in the combined company.

 

No option premium is payable by BSP for entering into the Option Agreement with the shareholders of Yrro. The Option may be exercised at the sole discretion of BSP. During the option period of six months, BSP will carry out a customary due diligence review to assess the benefits of exercising the Option. The consummation of any acquisition of business assets following exercise of the Option will be subject to, inter alia, the parties entering into a definitive agreement; and to approval by the shareholders of the Company for the issuance of the consideration shares.

 

If the Option is exercised, the current activities of the Company (i.e., ownership and development of the Sunrise Gardens Hotel in Aheloy, Bulgaria) will be divested into a new corporate entity."

 

Further announcements will be made in due course.

 

 

~ Ends ~

For further information please contact:

Craven House Capital Plc

Mark Pajak

www.Cravenhousecapital.com

 

Tel: 0203 286 8130

 

 

SI Capital

Broker

Nick Emerson

www.sicapital.co.uk

Tel: 01483 413500

 

SPARK Advisory Partners Limited

Nominated Adviser

Matt Davis/James Keeshan

www.Sparkadvisorypartners.com

 

 

Tel: 0203 368 3550

 

 

About Craven House Capital:

 The Company's Investing Policy is primarily to invest in or acquire a portfolio of companies, partnerships, joint ventures, businesses or other assets participating in the e-Commerce sector.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDFFFVFFLLTIII
UK 100

Latest directors dealings